Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 14.16 is in line with its 4-year average of 15.36, around the middle of its 4-year range (0.00–32.82).
As of the fiscal period ended Tuesday, June 30, 2026. 3.22% above its 12-month average of 13.72.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 14.16.
QUICK RATIO (ACID-TEST)
14.16
QUICK RATIO (ACID-TEST) AVG TTM
13.72
QUICK RATIO (ACID-TEST) AVG 3Y
14.77
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+3.22%
CURRENT VS 3Y AVG
-4.13%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.19
median of 736 covered companies
CURRENT VS SECTOR MEDIAN
+343.78%
vs the sector median at left
ArriVent BioPharma, Inc.
Market Cap
$659.73M
Quick Ratio (Acid-Test)
14.16
TTM Avg
13.72
3Y Avg
14.77
5Y Avg
N/A
Market Cap
$670.50M
Quick Ratio (Acid-Test)
4.79
TTM Avg
3.80
3Y Avg
3.38
5Y Avg
3.21
Market Cap
$672.27M
Quick Ratio (Acid-Test)
8.03
TTM Avg
12.16
3Y Avg
13.50
5Y Avg
14.42
Market Cap
$639.30M
Quick Ratio (Acid-Test)
16.82
TTM Avg
9.46
3Y Avg
14.12
5Y Avg
14.05
Market Cap
$681.21M
Quick Ratio (Acid-Test)
10.97
TTM Avg
8.63
3Y Avg
10.75
5Y Avg
10.66
Market Cap
$681.58M
Quick Ratio (Acid-Test)
5.53
TTM Avg
8.02
3Y Avg
10.47
5Y Avg
14.43
Market Cap
$633.46M
Quick Ratio (Acid-Test)
3.05
TTM Avg
5.21
3Y Avg
6.01
5Y Avg
5.25
Market Cap
$633.90M
Quick Ratio (Acid-Test)
31.45
TTM Avg
23.29
3Y Avg
26.88
5Y Avg
23.21
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | $659.73M | 14.16 | 13.72 | 14.77 | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $670.50M | 4.79 | 3.80 | 3.38 | 3.21 |
| OmniAb, Inc. (OABI)vs › | $654.55M | 4.80 | 4.27 | 4.36 | 3.29 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $672.27M | 8.03 | 12.16 | 13.50 | 14.42 |
| Aura Biosciences, Inc. (AURA)vs › | $639.30M | 16.82 | 9.46 | 14.12 | 14.05 |
| Helus Pharma Inc. (HELP)vs › | $681.21M | 10.97 | 8.63 | 10.75 | 10.66 |
| Annexon, Inc. (ANNX)vs › | $681.58M | 5.53 | 8.02 | 10.47 | 14.43 |
| Prime Medicine, Inc. (PRME)vs › | $633.46M | 3.05 | 5.21 | 6.01 | 5.25 |
| Climb Bio, Inc. (CLYM)vs › | $633.90M | 31.45 | 23.29 | 26.88 | 23.21 |
| Anteris Technologies Global Corp. (AVR)vs › | $690.28M | 14.20 | 2.59 | 2.42 | 2.06 |
Quick Ratio
14.16
Excludes inventory
Current Ratio
14.16
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 14.16 |
| 2026-03-31 | 13.95 |
| 2025-12-31 | 12.83 |
| 2025-09-30 | 14.90 |
| 2025-06-30 | 12.74 |
| 2025-03-31 | 14.34 |
| 2024-12-31 | 13.14 |
| 2024-09-30 | 19.28 |
| 2024-06-30 | 25.50 |
| 2024-03-31 | 32.82 |
| 2023-12-31 | 13.76 |
| 2023-09-30 | 17.82 |
| 2023-06-30 | 15.51 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 21.84 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
